医学
鼻腔给药
鼻漏
毒蕈碱乙酰胆碱受体
鼻塞
非过敏性鼻炎
过敏
抗胆碱药
麻醉
鼻粘膜
阿托品
受体拮抗剂
鼻子
敌手
鼻喷雾剂
药理学
抗胆碱能
毒蕈碱拮抗剂
鼻测压
临床试验
异丙托溴铵
哮喘
乙酰胆碱
鼻腔
重症监护医学
鼻减充血剂
作者
Xian Li,Xueyan Wang,Qintai Yang,Jianjun Chen,Hao Tian,Meiping Lu,Tingting Ma,Yana Zhang,Yue Zhou,Jiao Xia,Lei Cheng,Jian Li,Huanhai Liu,Jianfeng Liu,Zheng Liu,Wei Lv,Qianhui Qiu,Chengshuo Wang,Xiangdong Wang,Yu Xu
标识
DOI:10.5415/apallergy.0000000000000243
摘要
Allergic rhinitis (AR) is a prevalent inflammatory condition of the nasal mucosa, characterized by rhinorrhea, nasal congestion, sneezing, and itching. Among these symptoms, rhinorrhea and nasal congestion are the most common complaints of AR patients. By blocking acetylcholine binding with muscarinic (M) receptors, intranasal anticholinergics have been recommended by guidelines as an "add-on" or second-line therapy to control rhinorrhea in patients with AR. Bencycloquidium bromide is a highly selective M1/M3 receptor antagonist that can reduce excessive mucus secretion and suppress type 2 inflammation in AR, while also demonstrating efficacy in alleviating overall nasal symptoms. In this consensus, we systematically review the role of acetylcholine and M receptors in AR pathogenesis, the key findings from clinical trials on intranasal anticholinergics for AR management and the evidence-based recommendations from experts in Allergy and Rhinology, hoping to guide physicians in the standardized and precise use of intranasal anticholinergics for AR patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI